Vta1 Inhibitors
Chemical inhibitors of Vta1 can exert their effects through different mechanisms within the ubiquitin-proteasome system. Alsterpaullone acts by inhibiting cyclin-dependent kinases, which are enzymes that, when functioning normally, phosphorylate various substrates including proteins involved in the ubiquitin-proteasome pathway. By inhibiting these kinases, Alsterpaullone can indirectly reduce the activity of the ubiquitin-proteasome system, thereby impacting the function of Vta1. Similarly, MLN4924 targets the NEDD8-activating enzyme, which is essential for the neddylation process that regulates the activity of cullin-RING ligases within the ubiquitin-proteasome system. The inhibition of this enzyme can lead to disruptions in the regulation of these ligases, which in turn can affect the function of Vta1 within the pathway.
In addition to inhibitors that target regulatory enzymes of the ubiquitin-proteasome system, several compounds directly inhibit the proteasome itself. MG132, Bortezomib, Clasto-lactacystin β-lactone, Epoxomicin, Lactacystin, Velcade, Carfilzomib, Oprozomib, and ixazomib bind to the proteasome in various capacities, leading to an inhibition of its proteolytic activity. The proteasome is responsible for degrading polyubiquitinated proteins, and its inhibition leads to an accumulation of these proteins within the cell. This accumulation can saturate the ubiquitin-proteasome system, which indirectly affects the function of Vta1. As Vta1 is part of the machinery that assists in the clearance of ubiquitinated proteins, the presence of proteasome inhibitors can lead to an overload of substrates for Vta1, consequently influencing its ability to facilitate protein degradation effectively within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a known inhibitor of cyclin-dependent kinases (CDKs). Vta1 is involved in the ubiquitin-proteasome system, where CDKs can regulate proteins that are involved in the cell cycle and thus ubiquitination processes. Inhibition of CDKs can reduce the activity of the ubiquitin-proteasome system, indirectly inhibiting the function of Vta1. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor. By inhibiting the proteasome, MG132 can lead to an accumulation of polyubiquitinated proteins, which may saturate the ubiquitin-proteasome system and indirectly inhibit Vta1's associated protein degradation pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib specifically inhibits the 26S proteasome. Since Vta1 is involved in protein degradation via the ubiquitin-proteasome system, the inhibition of the proteasome by Bortezomib can indirectly inhibit the function of Vta1 by preventing the degradation of proteins that Vta1 would typically help process. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits the NEDD8-activating enzyme, which is crucial for neddylation that regulates the activity of cullin-RING ligases (CRLs) within the ubiquitin-proteasome system. Since Vta1 is involved in this system, inhibition of neddylation can indirectly inhibit the function of Vta1 by disrupting the regulation of CRLs. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Clasto-lactacystin β-lactone irreversibly inhibits the proteasome. This leads to a decrease in the degradation of ubiquitinated proteins, which can indirectly inhibit the function of Vta1 as it is part of the system that normally clears these proteins. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor. It blocks the chymotrypsin-like activity of the proteasome, leading to an accumulation of proteins destined for degradation. As Vta1 is involved in the ubiquitin-proteasome pathway, the inhibition of the proteasome by Epoxomicin can indirectly inhibit the function of Vta1. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is an irreversible proteasome inhibitor. The inhibition of the proteasome's function can indirectly inhibit Vta1 by causing a buildup of proteins that would otherwise be degraded by the ubiquitin-proteasome pathway, potentially interfering with the normal function of Vta1. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is a proteasome inhibitor. It binds to and inhibits the proteolytic core of the proteasome, leading to an accumulation of ubiquitinated proteins. This can indirectly inhibit the function of Vta1 by impeding the degradation pathway of the ubiquitin-proteasome system in which Vta1 is involved. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
ixazomib is a selective and reversible proteasome inhibitor. It inhibits the proteasome activity, thereby causing a buildup of proteins that are to be degraded by the ubiquitin-proteasome system. This can indirectly inhibit the function of Vta1, as it plays a role in the clearance of ubiquitinated proteins through this system. | ||||||